- Conditions
- Autoimmune Epilepsy
- Interventions
- Intravenous Immunoglobulin, Placebos, Normal Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 66
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza (Pandemic)
- Interventions
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
- Conditions
- SLE; Drug
- Interventions
- KPG-818 low dose in phase 1b, KPG-818 mid dose in phase 1b, KPG-818 high dose in phase 1b, KPG-818 ultra-high dose in phase 1b, KPG-818 low dose in phase 2a, KPG-818 mid dose in phase 2a, KPG-818 high dose in phase 2a, KPG-818 Placebo in phase 2a
- Drug
- Lead sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more
- Conditions
- Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
- Interventions
- AZD0914, Moxifloxacin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Chronic Hepatitis C
- Interventions
- NM283 plus Peg-IFNα-2a
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 114 participants
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Fairfax, Virginia
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg, Arikayce™ 140 mg, Placebo for 70 mg / 140 mg
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more
- Conditions
- Osteoporosis
- Interventions
- Zoledronic acid, Placebo, Teriparatide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 45 Years to 89 Years · Female only
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
- Conditions
- Miscarriage, Recurrent, Abortion, Habitual
- Interventions
- Gamimune N or Gamunex 10%, normal saline
- Biological · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
- Interventions
- Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
- Drug · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
- Conditions
- Vaping
- Interventions
- Discussion of point-of-care ultrasound lung findings
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO4588161
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Ulcerative Colitis
- Interventions
- Tilpisertib Fosmecarbil, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 35
- States / cities
- Sun City, Arizona • Chula Vista, California • Coronado, California + 29 more
- Conditions
- Clostridium Difficile
- Interventions
- C. difficile vaccine with adjuvant, placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more
- Conditions
- Constipation - Functional
- Interventions
- CDD-2101
- Drug
- Lead sponsor
- Centre for Chinese Herbal Medicine Drug Development Limited
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Cardiovascular Outcomes
- Interventions
- Niaspan, Placebo
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 41
- States / cities
- Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
- Conditions
- Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
- Interventions
- Methenamine Hippurate 1 g tablet, Placebo tablet
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Obesity, Overweight
- Interventions
- NNC0487-0111, Placebo (NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus
- Interventions
- HM11260C, Placebo, Victoza
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- California City, California
- Conditions
- Arterial Catheterization
- Interventions
- Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline
- Drug
- Lead sponsor
- Medical University of Vienna
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio